The use of bisphosphonates to meet orthopaedic challenges

MiR-25 overexpression inhibits titanium particle-induced osteoclast differentiation via down-regulation of mitochondrial calcium uniporter in vitro

“…Bisphosphonates have been used clinically to treat osteolysis induced by osteoporosis and some tumors, as they function to inhibit bone adsorption by osteoclasts. However, these drugs have troublesome side effects, such as gastrointestinal adverse reactions and nephrotoxicity, and accurate data supporting their application to prevent and treat osteolysis are lacking [ 25 , 26 ]. Two alternatives, osteoprotegerin-Fc (OPG-Fc) and anti-RANKL (receptor activator of NF-κB ligand) therapy represent a major clinical strategy for inhibiting osteoclast differentiation.…”

Atypical femoral fractures: Another brick in the wall : On aspects of healing, treatment strategies and surveillance

“…In summary, there is no good evidence indicating that bisphosphonates impact negatively on fracture healing with regard to time to union and union strength (Wilkinson, 2020, Kates and Ackert-Bicknell, 2016, Duckworth et al, 2019.…”

Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial

“…To date, the most extensively investigated group of drugs explored are the bisphosphonates. Whilst observational studies have associated bisphosphonate use with a lower incidence of prosthesis revision, 6 these findings are not supported by clinical trial data. Rubash et al, in a randomised clinical trial of 123 participants (78 men, 45 women, mean age 63 years) with established femoral osteolytic lesions at 16 centres in the United States, found that daily oral administration of the bisphosphonate alendronate (10mg or 35mg versus placebo) did not affect change in radiological lesion size, visual analogue pain score, or likelihood of progression to revision surgery over 18 months.…”